Prior Authorization Request Form for
capmatinib **(Tabrecta)**

JOHNS HOPKINS MEDICINE
JOHNS HOPKINS HEALTHCARE
7231 Parkway Drive, Suite 100, Hanover, MD 21076

USFHP Pharmacy Prior Authorization Form

FAX Completed Form and Applicable Progress Notes to: (410) 424-4037

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

Questions? Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Step 1 **Please complete patient and physician information** (please print):

Patient Name: _____ Physician Name: _____
Address: _____ Address: _____
_____ _____
Sponsor ID # _____ Phone #: _____
Date of Birth: Secure Fax #:

Step 2 **Please complete the clinical assessment:**

1. Is the patient greater than or equal to 18 years of age?	☐ Yes Proceed to question **2**	☐ No **STOP** **Coverage not approved**
2. Is the requested medication prescribed by or in consultation with a hematologist or oncologist?	☐ Yes Proceed to question **3**	☐ No **STOP** **Coverage not approved**
3. Does the patient have a diagnosis of metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping?	☐ Yes Proceed to question **4**	☐ No Proceed to question **5**
4. Has the diagnosis been detected by an FDA-approved test?	☐ Yes Proceed to question **7**	☐ No **STOP** **Coverage not approved**
5. Please provide the indication or diagnosis.	_____ Proceed to question **6**	
6. Is the diagnosis cited in the National Comprehensive Cancer Network (NCCN) guidelines as a category 1, 2A, or 2B recommendation?	☐ Yes Proceed to question **7**	☐ No **STOP** **Coverage not approved**
7. Will the patient be monitored for Interstitial Lung Disease (ILD)/Pneumonitis and hepatotoxicity?	☐ Yes Proceed to question **8**	☐ No **STOP** **Coverage not approved**

Prior Authorization Request Form for capmatinib **(Tabrecta)**

8. Is the provider aware and has counseled the patient that capmatinib can cause photosensitivity and has counseled patients to avoid direct UV exposure?	☐ Yes Proceed to question **9**	☐ No **STOP** **Coverage not approved**
9. Is the patient of childbearing potential?	☐ Yes Proceed to question **10**	☐ No **Sign and date below**
10. What is the patient's gender?	☐ Male – Proceed to question **11** ☐ Female – Proceed to question **12**	
11. Will the patient use effective contraception during treatment and for at least 1 week after the cessation of therapy?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**
12. Will the patient use effective contraception during treatment and for at least 1 week after the cessation of therapy?	☐ Yes Proceed to question **13**	☐ No **STOP** **Coverage not approved**
13. Is the patient pregnant?	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **14**
14. Has it been confirmed that the patient is not pregnant by (-) HCG?	☐ Yes Proceed to question **15**	☐ No **STOP** **Coverage not approved**
15. Will the patient not breastfeed during treatment and for at least 1 week after the cessation of treatment?	☐ Yes **Sign and date below**	☐ No **STOP** **Coverage not approved**

Step 3 **I certify the above is true to the best of my knowledge.**
Please sign and date:

_____ _____
Prescriber Signature Date

[11 November 2020]

For Internal Use Only	
☐ Approved:	Duration of Approval: _____month(s)
☐ Denied:	Authorized By:
☐ Incomplete/Other:	PA#:
Date Faxed to MD:	Date Decision Rendered: